Does the media refer more to AXSM or MBX?

In the previous week, Axsome Therapeutics had 7 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Axsome Therapeutics' score of 0.99 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MBX or RDY?

MBX Biosciences presently has a consensus price target of $77.00, suggesting a potential upside of 30.46%. Given MBX Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MBX Biosciences 2 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.77 Dr. Reddy's Laboratories 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media favor MBX or RDY?

In the previous week, MBX Biosciences had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of 0.86 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dr. Reddy's Laboratories 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer MBX or CRNX?

In the previous week, MBX Biosciences and MBX Biosciences both had 4 articles in the media. Crinetics Pharmaceuticals' average media sentiment score of 1.37 beat MBX Biosciences' score of 1.09 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, BLTE or MBX?

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A MBX Biosciences N/A N/A -$86.97M -$2.41 N/A

Is BLTE or MBX more profitable?

Belite Bio's return on equity of -11.84% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% MBX Biosciences N/A -26.02% -24.94%

Does the media favor BLTE or MBX?

In the previous week, Belite Bio had 15 more articles in the media than MBX Biosciences. MarketBeat recorded 19 mentions for Belite Bio and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Belite Bio's score of 0.39 indicating that MBX Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 6 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is MBX or LNTH more profitable?

Lantheus has a net margin of 17.69% compared to MBX Biosciences' net margin of 0.00%. Lantheus' return on equity of 28.10% beat MBX Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Lantheus 17.69% 28.10% 14.35%

Does the media prefer MBX or LNTH?

In the previous week, Lantheus had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Lantheus' score of 0.94 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

MBX Biosciences (MBX) Competitors

$59.02 -1.92 (-3.15%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$59.02 +0.00 (+0.01%)

As of 09/11/2026 07:30 PM Eastern

Compare

MBX vs. AXSM, RDY, CRNX, BLTE, and LNTH

Should you buy MBX Biosciences stock or one of its competitors? MBX Biosciences's main competitors and comparable companies include Axsome Therapeutics (AXSM), Dr. Reddy's Laboratories (RDY), Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), and Lantheus (LNTH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does MBX Biosciences compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and MBX Biosciences (NASDAQ:MBX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

In the previous week, Axsome Therapeutics had 7 more articles in the media than MBX Biosciences. MarketBeat recorded 11 mentions for Axsome Therapeutics and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Axsome Therapeutics' score of 0.99 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Axsome Therapeutics presently has a consensus price target of $267.60, indicating a potential upside of 21.22%. MBX Biosciences has a consensus price target of $77.00, indicating a potential upside of 30.46%. Given MBX Biosciences' higher possible upside, analysts clearly believe MBX Biosciences is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

81.5% of Axsome Therapeutics shares are held by institutional investors. 20.6% of Axsome Therapeutics shares are held by insiders. Comparatively, 31.1% of MBX Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Axsome Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market.

MBX Biosciences has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. MBX Biosciences' return on equity of -26.02% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
MBX Biosciences	N/A	-26.02%	-24.94%

MBX Biosciences has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	18.11	-$183.17M	-$3.75	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Summary

MBX Biosciences beats Axsome Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

MBX Biosciences (NASDAQ:MBX) and Dr. Reddy's Laboratories (NYSE:RDY) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, dividends, institutional ownership, earnings, valuation and analyst recommendations.

MBX Biosciences presently has a consensus price target of $77.00, suggesting a potential upside of 30.46%. Given MBX Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe MBX Biosciences is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Dr. Reddy's Laboratories	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

MBX Biosciences has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Dr. Reddy's Laboratories has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Dr. Reddy's Laboratories	$331.19B	0.03	$456M	$0.44	27.06

Dr. Reddy's Laboratories has a net margin of 10.15% compared to MBX Biosciences' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 9.49% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Dr. Reddy's Laboratories	10.15%	9.49%	6.32%

3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, MBX Biosciences had 1 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 4 mentions for MBX Biosciences and 3 mentions for Dr. Reddy's Laboratories. MBX Biosciences' average media sentiment score of 1.09 beat Dr. Reddy's Laboratories' score of 0.86 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dr. Reddy's Laboratories	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Dr. Reddy's Laboratories beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

MBX Biosciences (NASDAQ:MBX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

MBX Biosciences has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. MBX Biosciences' return on equity of -26.02% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MBX Biosciences currently has a consensus price target of $77.00, indicating a potential upside of 30.46%. Crinetics Pharmaceuticals has a consensus price target of $81.00, indicating a potential downside of 4.65%. Given MBX Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe MBX Biosciences is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

In the previous week, MBX Biosciences and MBX Biosciences both had 4 articles in the media. Crinetics Pharmaceuticals' average media sentiment score of 1.37 beat MBX Biosciences' score of 1.09 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has higher earnings, but lower revenue than Crinetics Pharmaceuticals. MBX Biosciences is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

MBX Biosciences has a beta of 0.04, indicating that its stock price is 96% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Summary

MBX Biosciences beats Crinetics Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does MBX Biosciences compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and MBX Biosciences (NASDAQ:MBX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Belite Bio currently has a consensus target price of $218.73, suggesting a potential upside of 25.86%. MBX Biosciences has a consensus target price of $77.00, suggesting a potential upside of 30.46%. Given MBX Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe MBX Biosciences is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77

In the previous week, Belite Bio had 15 more articles in the media than MBX Biosciences. MarketBeat recorded 19 mentions for Belite Bio and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Belite Bio's score of 0.39 indicating that MBX Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	6 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio's return on equity of -11.84% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
MBX Biosciences	N/A	-26.02%	-24.94%

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 31.1% of MBX Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Belite Bio is trading at a lower price-to-earnings ratio than MBX Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, MBX Biosciences has a beta of 0.04, meaning that its stock price is 96% less volatile than the broader market.

Summary

MBX Biosciences beats Belite Bio on 9 of the 14 factors compared between the two stocks.

How does MBX Biosciences compare to Lantheus?

MBX Biosciences (NASDAQ:MBX) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

Lantheus has a net margin of 17.69% compared to MBX Biosciences' net margin of 0.00%. Lantheus' return on equity of 28.10% beat MBX Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Lantheus	17.69%	28.10%	14.35%

MBX Biosciences presently has a consensus price target of $77.00, suggesting a potential upside of 30.46%. Lantheus has a consensus price target of $108.11, suggesting a potential upside of 7.84%. Given MBX Biosciences' stronger consensus rating and higher probable upside, research analysts plainly believe MBX Biosciences is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

MBX Biosciences has a beta of 0.04, suggesting that its share price is 96% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, suggesting that its share price is 103% less volatile than the broader market.

Lantheus has higher revenue and earnings than MBX Biosciences. MBX Biosciences is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Lantheus	$1.54B	4.24	$233.56M	$4.14	24.21

In the previous week, Lantheus had 3 more articles in the media than MBX Biosciences. MarketBeat recorded 7 mentions for Lantheus and 4 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 1.09 beat Lantheus' score of 0.94 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are held by institutional investors. 31.1% of MBX Biosciences shares are held by insiders. Comparatively, 1.7% of Lantheus shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lantheus beats MBX Biosciences on 9 of the 16 factors compared between the two stocks.

Get MBX Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MBX vs. The Competition

Export

Metric	MBX Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.84B	$12.44B	$7.13B	$12.72B
Dividend Yield	N/A	2.62%	2.56%	11.15%
P/E Ratio	-24.49	799.75	275.24	25.29
Price / Sales	N/A	763.36	655.99	98.94
Price / Cash	N/A	89.25	77.04	51.44
Price / Book	7.18	10.39	10.33	6.20
Net Income	-$86.97M	$2.85B	$3.50B	$358.50M
7 Day Performance	-4.37%	-3.61%	-3.32%	-2.35%
1 Month Performance	-11.87%	0.86%	-0.41%	-2.77%
1 Year Performance	444.97%	3.47%	19.21%	7.63%

MBX Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MBX MBX Biosciences	2.8573 of 5 stars	$59.02 -3.2%	$77.00 +30.5%	+494.4%	$2.84B	N/A	N/A	63	Positive News
AXSM Axsome Therapeutics	3.795 of 5 stars	$206.68 -0.8%	$267.60 +29.5%	+79.5%	$10.83B	$638.50M	N/A	380
RDY Dr. Reddy's Laboratories	1.7107 of 5 stars	$11.97 -0.5%	N/A	-19.1%	$9.99B	$331.19B	27.21	27,527
CRNX Crinetics Pharmaceuticals	1.4863 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210	Positive News
BLTE Belite Bio	3.7457 of 5 stars	$193.61 +13.2%	$214.64 +10.9%	+153.5%	$7.80B	N/A	N/A	10	Analyst Forecast Insider Trade Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MBX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MBX Biosciences (MBX) Competitors

MBX vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does MBX Biosciences compare to Axsome Therapeutics?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Summary

How does MBX Biosciences compare to Belite Bio?

Summary

How does MBX Biosciences compare to Lantheus?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MBX Biosciences (MBX) Competitors

MBX vs. AXSM, RDY, CRNX, BLTE, and LNTH

How does MBX Biosciences compare to Axsome Therapeutics?

Does the media refer more to AXSM or MBX?

Do analysts recommend AXSM or MBX?

Do institutionals and insiders believe in AXSM or MBX?

Which has more volatility & risk, AXSM or MBX?

Is AXSM or MBX more profitable?

Which has preferable earnings & valuation, AXSM or MBX?

Summary

How does MBX Biosciences compare to Dr. Reddy's Laboratories?

Do analysts rate MBX or RDY?

Which has more volatility & risk, MBX or RDY?

Which has stronger earnings and valuation, MBX or RDY?

Is MBX or RDY more profitable?

Do institutionals & insiders have more ownership in MBX or RDY?

Does the media favor MBX or RDY?

Summary

How does MBX Biosciences compare to Crinetics Pharmaceuticals?

Is MBX or CRNX more profitable?

Do institutionals & insiders believe in MBX or CRNX?

Do analysts rate MBX or CRNX?

Does the media prefer MBX or CRNX?

Which has stronger valuation and earnings, MBX or CRNX?

Which has more risk & volatility, MBX or CRNX?

Summary

How does MBX Biosciences compare to Belite Bio?

Do analysts recommend BLTE or MBX?

Does the media favor BLTE or MBX?

Is BLTE or MBX more profitable?

Do insiders & institutionals believe in BLTE or MBX?

Which has better earnings and valuation, BLTE or MBX?

Which has more risk & volatility, BLTE or MBX?

Summary

How does MBX Biosciences compare to Lantheus?

Is MBX or LNTH more profitable?

Do analysts rate MBX or LNTH?

Which has more volatility & risk, MBX or LNTH?

Which has stronger valuation & earnings, MBX or LNTH?

Does the media prefer MBX or LNTH?

Do institutionals & insiders hold more shares of MBX or LNTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MBX vs. The Competition

MBX Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools